Vorapaxar did not reduce the first occurrence of the primary endpoint of CVD , MI , stroke , revascularization , or rehospitalization for recurrent ischemia , but reduced the secondary composite endpoint of CVD , MI , or stroke ( @ % vorapaxar vs. @ % placebo ; hazard ratio -LSB- HR -RSB- , @ ; @ % confidence interval -LSB- CI -RSB- , @ to @ ; P = @ ; number needed to treat -LSB- NNT -RSB- , @ ) .